Amneal Pharmaceuticals, Inc. (AMRX) Added to S&P SmallCap 600 Index, Boosting Investor Visibility

Core Insights - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is recognized as one of the 7 cheap pharmaceutical stocks to buy according to hedge funds [1] - JP Morgan has raised the price target for AMRX by $4 while maintaining a Buy rating [2] - The company has been added to the S&P SmallCap 600 Index, which is expected to enhance its visibility to investors and improve trading liquidity [3][8] Company Developments - Amneal Pharmaceuticals focuses on developing, manufacturing, and marketing generic and specialty branded medicines across various therapeutic areas, emphasizing cost-effective access and innovation [5] - A research collaboration and option agreement was established with KeifeRx to develop KFRX06, a preclinical candidate targeting LRRK2, which is associated with Parkinson's disease [4]